^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    GnRH stimulant

    Related drugs:
    2ms
    Celestial-1: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation (clinicaltrials.gov)
    P1, N=310, Terminated, Ferring Pharmaceuticals | N=600 --> 310 | Trial completion date: Sep 2026 --> Sep 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Sep 2025; This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    2ms
    Celestial-2: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation. (clinicaltrials.gov)
    P1, N=106, Terminated, Ferring Pharmaceuticals | N=200 --> 106 | Trial completion date: Jul 2026 --> Sep 2025 | Recruiting --> Terminated | Trial primary completion date: May 2026 --> Sep 2025; This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    6ms
    Observational Study on the Injection Experience and Quality of Life of Breast Cancer Patients After Switching from Goserelin Acetate Sustained-Release Implants to Injectable Goserelin Microspheres (ChiCTR2500103194)
    P4, N=50, Not yet recruiting, The Second Affiliated Hospital of Dalian Medical University; No. 467, Zhongshan Road, Shahekou District, Dalian City, Liaoning Province
    New P4 trial • HEOR
    |
    ER (Estrogen receptor)
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    6ms
    Goserelin Extended-Release Microspheres versus Sustained-Release Implant in Prostate Cancer: Real-World Evidence on Efficacy and Safety (ChiCTR2500100634)
    P4, N=50, Not yet recruiting, Aerospace Center Hospital; Aerospace Center Hospital
    New P4 trial • HEOR • Real-world evidence
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    7ms
    Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    Eligard (leuprolide acetate) • bicalutamide • goserelin acetate • Viadur (leuprorelin implant)
    8ms
    Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study (clinicaltrials.gov)
    P=N/A, N=400, Active, not recruiting, Qianfoshan Hospital
    New trial • HEOR • Real-world evidence
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    10ms
    SATURN: Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    abiraterone acetate • Eligard (leuprolide acetate) • apalutamide • Viadur (leuprorelin implant)
    12ms
    Celestial-1: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation (clinicaltrials.gov)
    P1, N=600, Recruiting, Ferring Pharmaceuticals | Trial completion date: Sep 2027 --> Sep 2026
    Trial completion date
    over1year
    Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    Eligard (leuprolide acetate) • Viadur (leuprorelin implant)
    over1year
    Celestial-2: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation. (clinicaltrials.gov)
    P1, N=200, Recruiting, Ferring Pharmaceuticals
    New P1 trial
    over1year
    Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer (clinicaltrials.gov)
    P3, N=154, Recruiting, Dongkook Pharmaceutical Co., Ltd.
    New P3 trial
    |
    leuprolide acetate for depot suspension
    over1year
    Celestial-1: An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation (clinicaltrials.gov)
    P1, N=600, Recruiting, Ferring Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open